CMPS Stock — COMPASS Pathways Plc: Cash, EV, Pipeline

Share price

$15.19

Market cap

$2,103.5M

Cash

$433.3M

Enterprise value

$1,720.9M

Balance sheet

Cash	$433.3M
Debt	$50.7M
Net cash	$382.6M
Enterprise value	$1,720.9M
Basic shares	135.7M shares
Fully diluted shares	217.6M shares
Fully diluted market cap	$3,304.7M
Cash per share	$3.19

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CMPS daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Dec 13, 2028 - Jan 24, 2029	COMP360 psilocybin	Phase 2/3	PTSD - Post Traumatic Stress Disorder; PTSD; PTSD Symptoms	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

COMP360

Phase 3 · Active Modality: psilocybin therapy

Target 5-HT2A

Indications

treatment-resistant depression (TRD) (Phase 3)
post-traumatic stress disorder (PTSD) (Phase 2/3)

Status note Single asset company (non-COMP360 preclinical/discovery work stopped Q4 2024). TRD: two pivotal trials (COMP005 single 25mg; COMP006 repeat-dose); Part B COMP006 results announced July 2026; rolling NDA submission in preparation (no submission date stated). PTSD: open-label Phase 2 completed; Phase 2b/3 trial planned. FDA Breakthrough Therapy designation (2018) for TRD.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Psilocybin
Lead indication	Treatment Resistant Depression
Lead phase	Phase 3
Active trials	3
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05711940	Phase 3	Active, not recruiting	Sponsor	COMPASS Pathways	—	Treatment Resistant Depression	—
NCT07570654	Phase 2/3	Recruiting	Sponsor	COMPASS Pathways	—	PTSD - Post Traumatic Stress Disorder; PTSD; PTSD Symptoms	—
NCT05733546	Phase 2	Active, not recruiting	Sponsor	COMPASS Pathways	—	Major Depressive Disorder	—
NCT06247839	Phase 3	Recruiting	Collaborator	Sharmin Ghaznavi	—	Major Depressive Disorder	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for COMPASS Pathways on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	10,700,974	+68,584	1.29%	2026-08-14
Logos Global Management	2,250,000	+2,250,000	1.37%	2026-08-14
Ikarian Capital	15,000	-660,000	0.03%	2026-08-14
Baker Bros. Advisors	0	-2,344,720	0.00%	2026-08-14
OrbiMed Advisors	0	-1,150,646	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

CMPS — COMPASS Pathways Plc